The phase number of the RCTs, dosage and administration details of PD-1 inhibitors, chemotherapy strategy, radiotherapy details, and cancer characteristics such as T category, N category, tumor location (proximal or distal), and MMR status are provided in Table 1. This evidence concerns the gene PDCD1 and neoplasm.